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CORRESPONDENCE
Pulse-spray Pharmacomechanical Thrombolysis for
Proximal Deep Vein Thrombosis
I read with great interest the article ‘‘Yamada N, Ishi-
kura K, Ota S, Tsuji A, Nakamura M, Ito M, Isaka N,
Nakano T. Pulse-spray pharmacomechanical throm-
bolysis for proximal deep vein thrombosis. Eur J
Vasc Endovasc Surg 2006 Feb;31(2):204e11’’ I would
like to draw the readers attention to the following:
In the introduction and discussion section the
authors note that ‘‘only a few case reports have been
published’’ and referred this to the publication
‘‘Elsharawy M, Elzayat E. Early results of thrombolysis
vs anticoagulation in iliofemoral venous thrombosis.
A randomised clinical trial. Eur J Vasc Endovasc
Surg 2002 Sep;24(3):209e14’’. This study was not
a case report and is the first and only randomized con-
trolled study published so far. The study was
performed on 35 patients, which were randomised
to either catheter directed thrombolysis followed by
anticoagulation or to anticoagulation alone. The con-
clusion of this study was that patients treated with
catheter directed thrombolysis obtained better pa-
tency and venous competence than those treated with
standard anticoagulation.
In the patients and methods section the authors
attempted thrombolysis for patients with DVT dura-
tion up to 29 days. Before starting my study, all cases
in which I attempted thrombolysis with symptoms
more than 10 days failed. This is why I excluded
any patients with symptoms for more than 10 days
from my study. It would be interesting to know
how many cases in Yamada et al. experience had
symptoms for more than 10 days and how these pa-
tients responded to thrombolysis?
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Reply to Correspondence From M.A. Elsharawy re:
‘‘Pulse-spray pharmacomechanical Thrombolysis
for Proximal Deep Vein Thrombosis’’
We thank Dr Elsharawy for his designation of our
mistake and his interest concerning our article. As
he pointed out, their article is a randomized con-
trolled study which demonstrated the pulse-spray
thrombolysis was superior to systemic anticoagula-
tion in not only patency rate in 1 week and 6
months after treatment but also inhibition of venous
reflux for acute iliofemoral deep venous thrombosis
(DVT).1 We should apologize and correct our
mistake.
As demonstrated in Table 1, our study included
the patients whose symptom lasted for more than
10 days. 7 cases (23%) had symptoms more than
10 days. The average lytic rate among these 7 cases
was 91%. The lytic rate was 94% even in patient
whose symptom duration was 29 days. Bjarnason
H et al. reported that success rate of catheter-
directed thrombolysis for iliofemoral DVT was
86% for patients treated within 1 week, 79% with
symptoms for 1e2 weeks, 66% when the symptoms
had lasted for 3e4 weeks, and 33% if the symp-
toms had lasted for more than 4 weeks.2 And
they also described that thrombi older than 5 weeks
may not be as amenable to thrombolytic therapy as
those that were more recent in their article.2 Gross-
man C et al. reported high success rate of catheter-
directed thrombolysis for the acute and subacute
DVT (<4 weeks old) in their review article.3
Catheter-directed thrombolysis was successful in
88% (160/181) of the patients with clots less than
4 weeks old compared with 60% (15/25) of the
patients with clots more than 4 weeks old.3 It is
certain that venous thrombi must organize time-
dependently and the age of thrombi correlates with
treatment outcome. But the age of thrombi is not
always same as the duration of symptoms. If the
symptoms appeared by the deterioration of venous
605Correspondenceflow disturbance such as iliac compression, venous
thrombosis may propagate extensively more recently.
We consider that pharmacomechanical thrombolysis
might be attempted for the patient whose symptom
of DVT continued at least less than 1 month from
our study.
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